MARKET

GLYC

GLYC

Glycomimetics
NASDAQ
1.610
-0.110
-6.40%
After Hours: 1.660 +0.05 +3.11% 19:51 12/04 EST
OPEN
1.730
PREV CLOSE
1.720
HIGH
1.740
LOW
1.510
VOLUME
285.42K
TURNOVER
0
52 WEEK HIGH
4.160
52 WEEK LOW
1.110
MARKET CAP
103.67M
P/E (TTM)
-2.5291
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at GLYC last week (1127-1201)?
Weekly Report · 1d ago
GlycoMimetics' Uproleselan: Navigating Clinical And Financial Complexities In AML
Glycomimetics' uproleselan shows promise in acute myeloid leukemia, but phase 3 trial changes introduce data interpretation and regulatory complexities. Aml market growth and demand for new therapies are positives, but competition and market saturation are concerns. Financial health is stable short-term but precarious long-term.
Seeking Alpha · 11/27 23:51
Weekly Report: what happened at GLYC last week (1120-1124)?
Weekly Report · 11/27 12:07
Weekly Report: what happened at GLYC last week (1113-1117)?
Weekly Report · 11/20 12:03
Weekly Report: what happened at GLYC last week (1106-1110)?
Weekly Report · 11/13 11:54
Weekly Report: what happened at GLYC last week (1030-1103)?
Weekly Report · 11/06 12:02
Buy Rating for GlycoMimetics: Stable Financials and Promising Drug Candidate Uproleselan Drive Positive Outlook
TipRanks · 11/06 11:18
Glycomimetics: Quarterly report
Press release · 11/03 16:02
More
About GLYC
GlycoMimetics, Inc. is a clinical-stage biotechnology company, which is focused on the discovery and development of glycomimetic drugs. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer, and infection. Its drug candidates include Uproleselan, GMI-1359, GMI-1687, and Galectin Antagonists. It is developing Uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). Its GMI-1359 targets both E-selectin and a chemokine receptor known as CXCR4. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. The Company is engaged in advancing other preclinical-stage programs, including small-molecule glycomimetic compounds that inhibit the protein galectin-3.

Webull offers GlycoMimetics Inc stock information, including NASDAQ: GLYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLYC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GLYC stock methods without spending real money on the virtual paper trading platform.